EQ

Equillium is a pre-revenue, preclinical-stage biotech, not a business you can value on fundamentals. Management is explicit that it has "not yet generated product sales" and has burned to a $216.2M accumulated deficit. The entire story rides on EQ504, an aryl-hydrocarbon-receptor modulator that is only now heading toward a Phase 1 proof-of-mechanism study starting mid-2026, with first data ~6 months later. That is the earliest, most binary end of the risk spectrum: there is no efficacy data in humans, and the MD&A concedes it "cannot provide any assurances" the trial will read out on time or favorably. The reported ~$41M "revenue" is legacy collaboration income, not durable product sales, so the 4.5x P/S is meaningless as a valuation anchor.

The financials confirm a going-concern-style profile kept alive only by continuous equity issuance. FY2025 net loss widened 177.6% to -$22.4M, operating cash flow was -$22.7M, ROE is -78.3%, and the company plainly states it "will need to raise additional capital." Cash was $30.3M at year-end, boosted to roughly $65M pro forma by the ~$35M March 2026 private placement — perhaps two years of runway, but only because shareholders are being diluted relentlessly. Shares outstanding jumped 77.6% in a year, and that understates the damage: the August 2025 placement priced stock at just $0.57 and layered on 30.8M pre-funded warrants, and the March 2026 deal added 17.7M more warrants at $1.854. A second August closing for up to $20M more looms. Today's $2.91 price sits far above where insiders funded the company months ago, so the recent run-up has already discounted optimism the clinic has not earned.